Johnson & Johnson Phase 3 data released: one jab, 72% efficacy
The data showed that, starting at the 14th day, recipients were 66% protected against moderate to severe complications from COVID-19.
A health worker draws a dose of the AstraZeneca's coronavirus disease (COVID-19) vaccine, at the vaccination center in the Newcastle Eagles Community Arena, in Newcastle upon Tyne, Britain, January 30, 2021.(photo credit: REUTERS/LEE SMITH)ByJERUSALEM POST STAFF
